DK2841114T3 - Selvhærdende bioaktive cementsammensætninger med delvist deacetyleret chitin som knogletransplantaterstatninger - Google Patents
Selvhærdende bioaktive cementsammensætninger med delvist deacetyleret chitin som knogletransplantaterstatninger Download PDFInfo
- Publication number
- DK2841114T3 DK2841114T3 DK13724891.0T DK13724891T DK2841114T3 DK 2841114 T3 DK2841114 T3 DK 2841114T3 DK 13724891 T DK13724891 T DK 13724891T DK 2841114 T3 DK2841114 T3 DK 2841114T3
- Authority
- DK
- Denmark
- Prior art keywords
- bone
- range
- pdc
- acid
- bone cement
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 121
- 210000000988 bone and bone Anatomy 0.000 title claims description 102
- 239000004568 cement Substances 0.000 title claims description 40
- 229920002101 Chitin Polymers 0.000 title claims description 23
- 230000000975 bioactive effect Effects 0.000 title description 2
- 239000007788 liquid Substances 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 40
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 30
- 230000006196 deacetylation Effects 0.000 claims description 24
- 238000003381 deacetylation reaction Methods 0.000 claims description 24
- 239000001506 calcium phosphate Substances 0.000 claims description 22
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 21
- 235000011010 calcium phosphates Nutrition 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 17
- 239000002639 bone cement Substances 0.000 claims description 17
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 15
- 230000035876 healing Effects 0.000 claims description 15
- 230000002188 osteogenic effect Effects 0.000 claims description 14
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000008439 repair process Effects 0.000 claims description 4
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000003181 biological factor Substances 0.000 claims 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 description 31
- 239000000463 material Substances 0.000 description 28
- 229920001661 Chitosan Polymers 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 22
- 210000004373 mandible Anatomy 0.000 description 19
- 239000002131 composite material Substances 0.000 description 18
- 238000001356 surgical procedure Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000000306 component Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 210000002303 tibia Anatomy 0.000 description 12
- 239000011800 void material Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000010603 microCT Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 210000001847 jaw Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 230000035515 penetration Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000010392 Bone Fractures Diseases 0.000 description 6
- 102000012286 Chitinases Human genes 0.000 description 6
- 108010022172 Chitinases Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 230000033558 biomineral tissue development Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000000399 orthopedic effect Effects 0.000 description 4
- 230000000278 osteoconductive effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000005422 Foreign-Body reaction Diseases 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000005009 osteogenic cell Anatomy 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 229960002901 sodium glycerophosphate Drugs 0.000 description 3
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001175 calcium sulphate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000012669 compression test Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101710203678 Chitinase-like protein Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 241001351439 Oneida Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- GEKBIENFFVFKRG-UHFFFAOYSA-L disodium;2,3-dihydroxypropyl phosphate Chemical compound [Na+].[Na+].OCC(O)COP([O-])([O-])=O GEKBIENFFVFKRG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000035929 gnawing Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001460 masseteric effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- -1 polydimethylsiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
- A61L24/0084—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/24—Acids; Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Knoglecementsammensætningskit til medicinsk knoglehelingsbehandling, omfattende a. en faststoffraktion omfattende delvist deacetyleret chitin (PDC) med en grad af deacetylering i området 40-75 % og calciumphosphat; b. en sur væskefraktion omfattende vand og en syre; hvilke fraktioner er tilvejebragt i separate hætteglas, der skal blandes før anvendelse, hvor vægt:vægt-forholdet mellem faststoffraktionen og væskefraktionen er i området fra 1:2 til 1:3.
2. Knoglecementsammensætningskit ifølge krav 1, hvor PDC har en grad af deacetylering i området 40-60 % og fortrinsvis omkring 50 %.
3. Knoglecementsammensætningskit ifølge krav 1, hvor faststoffraktionen omfatter i området 3-30 vægt-% PDC, fortrinsvis i området 5-15 vægt-%.
4. Knoglecementsammensætningskit ifølge et hvilket som helst af kravene 1- 3, hvor væskefraktionen omfatter en eller flere syrer udvalgt fra gruppen bestående af phosphorsyre, saltsyre, ascorbinsyre, mælkesyre, eddikesyre, myresyre, propionsyre, æblesyre, citronsyre og glutaminsyre.
5. Knoglecementsammensætningskit ifølge et hvilket som helst af kravene 1- 4, hvor væskefraktionen har en surhedsgrad svarende til mindst 5 vægt-% phosphorsyre.
6. Knoglecementsammensætningskit ifølge krav 1, hvor væskefraktionen yderligere omfatter calciumhydroxid.
7. Knoglecementsammensætningskit ifølge et hvilket som helst af de foregående krav, omfattende en mængde af PDC, som er i området 0,5-10 vægt-% af de kombinerede fraktioner, fortrinsvis i området ca. 1-5 vægt-%.
8. Knoglecementsammensætningskit ifølge et hvilket som helst af de foregående krav, hvor PDC er blevet opløst og udfældet.
9. Knoglecementsammensætningskit ifølge et hvilket som helst af de foregående krav, hvor calciumphosphatet omfatter et eller flere blandt tetracalci-umphosphat, alfa-tricalciumphosphat og andre calciumphosphater, der kan danne udfældningsprodukter af hydroxyapatatit og/eller brushit.
10. Knoglecementsammensætningskit ifølge krav 1, hvor sammensætningen begynder at hærde ved rumtemperatur efter blanding og har en hærdningstid ved rumtemperatur i området ca. 15-30 minutter, hvilken sammensætning har en viskositet efter blanding som bestemt ved injicerbarhed, som er mindre end 30 N målt med en 5 ml-B.Braun-sprøjte med 12 mm ID og 2 mm åbning.
11. Sammensætningskit ifølge et hvilket som helst af de foregående krav, hvor sammensætningen ikke indeholder knoglemorfogent protein eller anden biologisk faktor udvalgt blandt knoglemarv, blod, knogler og osteogene proteiner.
12. Sammensætningskit ifølge et hvilket som helst af de foregående krav, yderligere omfattende calciumsulfat i faststoffraktionen.
13. Knoglecementsammensætningskit ifølge et hvilket som helst af kravene 1-12 til anvendelse som et medikament til reparation og heling af knogler.
14. Knoglecementblanding omfattende: - en faststoffraktion omfattende delvist deacetyleret chitin (PDC) med en grad af deacetylering i området 40-75 % og calciumphosphat, og en sur væskefraktion omfattende vand og en syre, hvor vægt:vægt-forholdet mellem faststoffraktionen og væskefraktionen er i området fra 1:2 til 1:3, til dannelse af en blanding, som er en halvflydende eller pastalignende cementblanding, til anvendelse som et medikament til reparation og heling af knogler, hvor knoglecementblandingen skal anvendes på knoglestedet, der skal heles.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS50032 | 2012-04-23 | ||
| PCT/IS2013/050003 WO2013160917A1 (en) | 2012-04-23 | 2013-04-23 | Self-hardening bioactive cement compositions with partially deacetylated chitin as bone graft substitutes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2841114T3 true DK2841114T3 (da) | 2018-09-24 |
Family
ID=48485243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13724891.0T DK2841114T3 (da) | 2012-04-23 | 2013-04-23 | Selvhærdende bioaktive cementsammensætninger med delvist deacetyleret chitin som knogletransplantaterstatninger |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9474828B2 (da) |
| EP (1) | EP2841114B1 (da) |
| JP (1) | JP6232048B2 (da) |
| CN (2) | CN107320772A (da) |
| DK (1) | DK2841114T3 (da) |
| ES (1) | ES2688324T3 (da) |
| MX (1) | MX352422B (da) |
| PL (1) | PL2841114T3 (da) |
| PT (1) | PT2841114T (da) |
| WO (1) | WO2013160917A1 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025526752A (ja) * | 2022-08-11 | 2025-08-15 | ジーニス エイチエフ． | ３ｄプリントされた生体活性スキャホールド |
| KR102673344B1 (ko) * | 2023-09-06 | 2024-06-10 | 주식회사 메디팹 | 체내 이온감응성 조직 수복용 생체재료 제조용 조성물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3881707B2 (ja) | 1995-07-20 | 2007-02-14 | 学校法人松本歯科大学 | 骨形成促進剤の製造方法及び骨形成促進剤を用いた骨形成組成物の製造方法 |
| US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
| ATE243049T1 (de) | 1999-12-09 | 2003-07-15 | Biosyntech Canada Inc | Mineral-polymer hybrid-zusammensetzung |
| IS6085A (is) | 2001-09-26 | 2003-03-27 | Genis Ehf. | Lyfjablanda með kítósan óligómerum |
| ES2260616T3 (es) * | 2002-06-19 | 2006-11-01 | Dr.H.C. Robert Mathys Stiftung | Cemento hidraulico con base de fosfato de calcio destinado a uso quirurgico. |
| JP2006503614A (ja) | 2002-09-30 | 2006-02-02 | リージェン バイオテック インコーポレーテッド | 骨形成及び骨硬化促進用組成物 |
| IS7572A (is) * | 2004-11-29 | 2006-05-30 | Genis Ehf | Aðferð og efni til lækninga |
| SI1917218T1 (sl) * | 2005-06-14 | 2017-12-29 | Genis Hf. | Sestavki delno deacetiliranih hitinskih derivatov |
| WO2008063791A2 (en) * | 2006-10-13 | 2008-05-29 | Ndsu Research Foundation | Composites and methods of preparation and use thereof |
| CN101057979B (zh) * | 2007-04-03 | 2010-06-09 | 暨南大学 | 可注射自固化磷酸钙骨组织修复材料及其制备方法与应用 |
-
2013
- 2013-04-23 MX MX2014012728A patent/MX352422B/es active IP Right Grant
- 2013-04-23 PT PT13724891T patent/PT2841114T/pt unknown
- 2013-04-23 CN CN201710454216.9A patent/CN107320772A/zh active Pending
- 2013-04-23 CN CN201380029068.6A patent/CN104470550A/zh active Pending
- 2013-04-23 US US14/396,257 patent/US9474828B2/en active Active
- 2013-04-23 PL PL13724891T patent/PL2841114T3/pl unknown
- 2013-04-23 EP EP13724891.0A patent/EP2841114B1/en active Active
- 2013-04-23 WO PCT/IS2013/050003 patent/WO2013160917A1/en not_active Ceased
- 2013-04-23 JP JP2015507665A patent/JP6232048B2/ja active Active
- 2013-04-23 DK DK13724891.0T patent/DK2841114T3/da active
- 2013-04-23 ES ES13724891.0T patent/ES2688324T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6232048B2 (ja) | 2017-11-15 |
| EP2841114B1 (en) | 2018-06-13 |
| WO2013160917A1 (en) | 2013-10-31 |
| PL2841114T3 (pl) | 2018-12-31 |
| EP2841114A1 (en) | 2015-03-04 |
| MX352422B (es) | 2017-11-24 |
| PT2841114T (pt) | 2018-10-19 |
| US9474828B2 (en) | 2016-10-25 |
| ES2688324T3 (es) | 2018-10-31 |
| MX2014012728A (es) | 2015-01-15 |
| US20150217021A1 (en) | 2015-08-06 |
| CN104470550A (zh) | 2015-03-25 |
| CN107320772A (zh) | 2017-11-07 |
| JP2015514535A (ja) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011329054B2 (en) | Bone void fillers | |
| US20150238525A1 (en) | Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use | |
| US10695461B2 (en) | Dried implant composition and injectable aqueous implant formulation | |
| Ambrosio et al. | Injectable calcium-phosphate-based composites for skeletal bone treatments | |
| MX2007003099A (es) | Composicion de bio-material de propositos multiples. | |
| Bongio et al. | Subcutaneous tissue response and osteogenic performance of calcium phosphate nanoparticle-enriched hydrogels in the tibial medullary cavity of guinea pigs | |
| US10918592B2 (en) | Injectable aqueous implant formulation containing ascorbic acid | |
| Moussi et al. | Injectable macromolecule-based calcium phosphate bone substitutes | |
| NL2007850C2 (en) | Injectable calcium phosphate cement comprising glucono-delta-lactone. | |
| DK2841114T3 (da) | Selvhærdende bioaktive cementsammensætninger med delvist deacetyleret chitin som knogletransplantaterstatninger | |
| Rony et al. | Hyaluronic acid stimulates osseointegration of β-TCP in young and old ewes | |
| Setiawatie et al. | Carbonate hydroxyapatite-hyaluronic acid as bone healing accelerator: in-vitro and in-vivo studies on the alveolar bone of wistar rats | |
| WO2024067485A1 (en) | Injectable magnesium oxychloride cement foam (mocf) -derived scaffold for treating osteoporotic bone defects | |
| CN116549734A (zh) | 一种适用于骨修复的复合骨水泥及其制备方法 | |
| Chen et al. | Effects of chitosan-coated pressed calcium sulfate pellets combined with recombinant human bone morphogenetic protein 2 on bone formation in femoral condyle-contained bone defects | |
| Ezz et al. | Histological assessment of injectable macro-porous calcium phosphate cement (CPC) versus autogenous bone graft on healing of osseous defect (experimental animal study) | |
| RU2793772C2 (ru) | Высушенная композиция импланта и инъектируемый водный состав импланта для инъекции | |
| Dewi et al. | The newly bone formation with carbonate apatite-chitosan bone substitute in the rat tibia | |
| da Silva Oliveira | Development of an Injectable Modified Calcium Phosphate (Bonelike)-Dextrin Hydrogel Biomaterial for Bone Regenaration | |
| Choi et al. | Osteogenetic Effects of Calcium Sulfate, Demineralized Bone Matrix, and Calcium Metaphosphate in a Canine Femur with Unicortical Defects |